|

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

RECRUITINGSponsored by Indiana University
Actively Recruiting
SponsorIndiana University
Started2026-03-24
Est. completion2028-04
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites

Summary

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults ≥18 years of age
* Clinical diagnosis of T1D
* GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
* Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
* Willing and able to provide informed consent

Exclusion Criteria:

* No exclusion criteria other than those not meeting inclusion criteria above

Conditions2

DiabetesType 1 Diabetes

Locations7 sites

Hoag Memorial Hospital
Newport Beach, California, 92663
Brittany Dennis949-764-6896Brittany.Dennis@hoag.org
Emory University
sabeena usman404-251-8959sabeena.usman@emory.edu
Northwestern University
Evelyn Fronczyk312-908-9002evelyn.guevara@northwestern.edu
Maine Health Research Institute
Portland, Maine, 04102
Debra Burris207-662-2467debra.burris@mainehealth.org
Harvard Medical School
Grace Ordonez617-732-4245gordonez@bwh.harvard.edu

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.